{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:14:19Z","timestamp":1790612059295,"version":"4.1.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,2]]},"DOI":"10.7759\/cureus.68479","type":"journal-article","created":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T19:33:55Z","timestamp":1725305635000},"source":"Crossref","is-referenced-by-count":3,"title":["Dasatinib-Induced Bilateral Chylothorax: A Case Report"],"prefix":"10.7759","author":[{"given":"Caitlin E","family":"McGonegal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujatha","family":"Baskar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Chronic myeloid leukemia (CML). (2024). Accessed. July 6, 2024: https:\/\/www.cancer.org\/cancer\/types\/chronic-myeloid-leukemia.html."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2003.1.132","article-title":"Chronic myeloid leukemia","volume":"5","author":"Melo JV","year":"2003","unstructured":"Melo JV, Hughes TP, Apperley JF. Chronic myeloid leukemia. Hematology Am Soc Hematol Educ Program. 2003, 5:132-52. 10.1182\/asheducation-2003.1.132","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1023\/a:1008349405763","article-title":"Analysis of Philadelphia chromosome-negative BCR-ABL-positive chronic myelogenous leukemia by hypermetaphase fluorescence in situ hybridization","volume":"10","author":"Seong D","year":"1999","unstructured":"Seong D, Kantarjian HM, Albitar M, et al.. Analysis of Philadelphia chromosome-negative BCR-ABL-positive chronic myelogenous leukemia by hypermetaphase fluorescence in situ hybridization. Ann Oncol. 1999, 10:955-9. 10.1023\/a:1008349405763","journal-title":"Ann Oncol"},{"key":"ref4","unstructured":"Dasatinib. (2024). Accessed. July 15, 2024: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Dasatinib."},{"key":"ref5","unstructured":"Sprycel. (2024). Accessed. July 15, 2024: https:\/\/www.sprycel.com\/."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.12890\/2023_003921","article-title":"Dasatinib-induced chylothorax beyond 5 years of treatment: is there actually any limit?","volume":"10","author":"Garcia-Zamalloa A","year":"2023","unstructured":"Garcia-Zamalloa A, Basauri B, Urcelay G, Sainz A. Dasatinib-induced chylothorax beyond 5 years of treatment: is there actually any limit?. Eur J Case Rep Intern Med. 2023, 10:003921. 10.12890\/2023_003921","journal-title":"Eur J Case Rep Intern Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01096-2017","article-title":"Dasatinib increases endothelial permeability leading to pleural effusion","volume":"51","author":"Phan C","year":"2018","unstructured":"Phan C, Jutant EM, Tu L, et al.. Dasatinib increases endothelial permeability leading to pleural effusion. Eur Respir J. 2018, 51:14-6. 10.1183\/13993003.01096-2017","journal-title":"Eur Respir J"},{"key":"ref8","unstructured":"Chylothorax. (2023). Accessed. July 15, 2024: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK459206\/."},{"key":"ref9","unstructured":"PDGFRB platelet-derived growth factor receptor beta [Homo sapiens (human)]. (2024). Accessed. July 15, 2024: https:\/\/www.ncbi.nlm.nih.gov\/gene\/5159."},{"key":"ref10","article-title":"Harrison's Principles of Internal Medicine Self-Assessment and Board Review, 20th Edition","author":"Wiener C","year":"2018","unstructured":"Wiener C, JamesonJL, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J. Harrison's Principles of Internal Medicine Self-Assessment and Board Review, 20th Edition. McGraw Hill Education, New York, NY; 2018."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.6004\/jadpro.2013.4.6.8","article-title":"Bosutinib: a novel src\/abl kinase inhibitor for chronic myelogenous leukemia","volume":"4","author":"Steinbach A","year":"2013","unstructured":"Steinbach A, Clark SM, Clemmons AB. Bosutinib: a novel src\/abl kinase inhibitor for chronic myelogenous leukemia. J Adv Pract Oncol. 2013, 4:451-5. 10.6004\/jadpro.2013.4.6.8","journal-title":"J Adv Pract Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/286032-dasatinib-induced-bilateral-chylothorax-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T19:34:03Z","timestamp":1725305643000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/286032-dasatinib-induced-bilateral-chylothorax-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,2]]},"references-count":11,"URL":"https:\/\/doi.org\/10.7759\/cureus.68479","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,2]]}}}